Australian Therapeutic Goods Advisory Council

Related information

15 April 2015


On 16 July 2012, the Australian Government announced that it would establish an Australian Therapeutic Goods Advisory Council (the Council) to provide broad strategic advice to the TGA, with an emphasis on improving communications between the regulator and its key stakeholders.

The establishment of this committee was a key recommendation of the TGA Transparency Review and forms part of the roll-out of the reforms outlined in the plan for the TGA reforms: a blueprint for TGA's future, (the blueprint).

On 16 November 2012, the Parliamentary Secretary for Health and Ageing, The Hon. Catherine King MP announced the membership of the Council to be chaired by Australia's Chief Medical Officer, Professor Chris Baggoley.

Members of the Council were selected for their individual knowledge and extensive experience in areas as diverse as clinical practice, research, industry experience, business management, health consumer issues and public administration.



  • Professor Chris Baggoley Chair, Commonwealth Chief Medical Officer


  • Dr John Aloizos (membership expired 31/10/2015)
  • Associate Professor Lesley Braun (membership expired 31/10/2015)
  • Ms Lynelle Briggs (membership expired 31/10/2015)
  • Ms Karen Carey (membership expired 31/10/2015)
  • Mr Will DeLaat (membership expired 31/10/2015)
  • Professor Stephen Graves (membership expired 31/10/2015)
  • Professor Michael Kidd (membership expired 31/10/2015)
  • Professor Andrew McLachlan (membership expired 31/10/2015)
  • Ms Debbie Rigby (membership expired 31/10/2015)
  • Emeritus Professor Lloyd Sansom (membership expired 31/10/2015)
  • Ms Juliet Seifert (membership expired 31/10/2015)
  • Ms Anne Trimmer (membership expired 31/10/2015)
  • Professor John Wakerman (membership expired 31/10/2015)
  • Dr Janet Wale (membership expired 31/10/2015)

Terms of reference

The Council is to provide strategic advice to the TGA on:

  • matters relating to organisational planning, management initiatives, performance measures and quality improvement, including service standards and benchmarking;
  • increasing public awareness of the safe use of therapeutic goods;
  • engagement with stakeholders, including consumer health organisations, health practitioner organisations, industry organisations and companies, academia; and
  • emerging issues in public health and safety, regulatory policy and processes.

ATGAC meeting dates

To be advised

Media releases

More information

For more information, contact